OMERS Life Sciences

Stories

Zymeworks completes Theravance acquisition, adds COPD drug YUPELRI

As of October 2026: Holds $350 million non-recourse note secured by YUPELRI cash flows

Zymeworks, a Vancouver biotech built on research partnerships, now owns a commercial medicine. The Sept. 23 closing of its Theravance Biopharma acquisition added YUPELRI, a once-daily nebulized COPD treatment that posted $133.1 million in sales in the first half of 2026, plus the hospital sales team behind it.

Updated Oct 4